Drug Synergy of Tenofovir and Nanoparticle-based Antiretrovirals for HIV Prophylaxis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 May 1

PMID 23630586

Citations 31

Authors

Thanyanan Chaowanachan

Emily Krogstad

Cameron Ball

Kim A Woodrow

Affiliations

Soon will be listed here.

Abstract

Background: The use of drug combinations has revolutionized the treatment of HIV but there is no equivalent combination product that exists for prevention, particularly for topical HIV prevention. Strategies to combine chemically incompatible agents may facilitate the discovery of unique drug-drug activities, particularly unexplored combination drug synergy. We fabricated two types of nanoparticles, each loaded with a single antiretroviral (ARV) that acts on a specific step of the viral replication cycle. Here we show unique combination drug activities mediated by our polymeric delivery systems when combined with free tenofovir (TFV).

Methodology/principal Findings: Biodegradable poly(lactide-co-glycolide) nanoparticles loaded with efavirenz (NP-EFV) or saquinavir (NP-SQV) were individually prepared by emulsion or nanoprecipitation techniques. Nanoparticles had reproducible size (d ∼200 nm) and zeta potential (-25 mV). The drug loading of the nanoparticles was approximately 7% (w/w). NP-EFV and NP-SQV were nontoxic to TZM-bl cells and ectocervical explants. Both NP-EFV and NP-SQV exhibited potent protection against HIV-1 BaL infection in vitro. The HIV inhibitory effect of nanoparticle formulated ARVs showed up to a 50-fold reduction in the 50% inhibitory concentration (IC50) compared to free drug. To quantify the activity arising from delivery of drug combinations, we calculated combination indices (CI) according to the median-effect principle. NP-EFV combined with free TFV demonstrated strong synergistic effects (CI50 = 0.07) at a 1∶50 ratio of IC50 values and additive effects (CI50 = 1.05) at a 1∶1 ratio of IC50 values. TFV combined with NP-SQV at a 1∶1 ratio of IC50 values also showed strong synergy (CI50 = 0.07).

Conclusions: ARVs with different physicochemical properties can be encapsulated individually into nanoparticles to potently inhibit HIV. Our findings demonstrate for the first time that combining TFV with either NP-EFV or NP-SQV results in pronounced combination drug effects, and emphasize the potential of nanoparticles for the realization of unique drug-drug activities.

Citing Articles

Combinatorial Delivery of Docetaxel- and Erlotinib-Loaded Functionalized Nanostructured Lipid Carriers for the Treatment of Triple-Negative Breast Cancer Using Quality-by-Design Approach.

Chaudhuri A, Kumar D, Srivastava S, Kumar D, Patil U, Parmar A Pharmaceutics. 2024; 16(7).

PMID: 39065626 PMC: 11279545. DOI: 10.3390/pharmaceutics16070926.

Delivery and short-term maternal and fetal safety of vaginally administered PEG-PLGA nanoparticles.

Irvin-Choy N, Nelson K, Gleghorn J, Day E Drug Deliv Transl Res. 2023; 13(12):3003-3013.

PMID: 37365402 PMC: 10913101. DOI: 10.1007/s13346-023-01369-w.

Antiviral role of nanomaterials: a material scientist's perspective.

Aanish Ali M, Rehman N, Park T, Basit M RSC Adv. 2023; 13(1):47-79.

PMID: 36605642 PMC: 9769549. DOI: 10.1039/d2ra06410c.

The Promise of Nanotechnology in Personalized Medicine.

Ali Alghamdi M, Fallica A, Virzi N, Kesharwani P, Pittala V, Greish K J Pers Med. 2022; 12(5).

PMID: 35629095 PMC: 9142986. DOI: 10.3390/jpm12050673.

Formulation of Cabotegravir Loaded Gold Nanoparticles: Optimization, Characterization to In-Vitro Cytotoxicity Study.

Rawat P, Imam S, Gupta S J Clust Sci. 2022; 34(2):893-905.

PMID: 35493274 PMC: 9044393. DOI: 10.1007/s10876-022-02261-2.

References

Huisman M, Smit J, Wiltshire H, Hoetelmans R, Beijnen J, Schinkel A . P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol. 2001; 59(4):806-13. DOI: 10.1124/mol.59.4.806. View

Lusso P, Cocchi F, Balotta C, Markham P, Louie A, Farci P . Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J Virol. 1995; 69(6):3712-20. PMC: 189087. DOI: 10.1128/JVI.69.6.3712-3720.1995. View

Shah L, Amiji M . Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS. Pharm Res. 2006; 23(11):2638-45. DOI: 10.1007/s11095-006-9101-7. View

Palmer S, Margot N, Gilbert H, Shaw N, Buckheit Jr R, Miller M . Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance. AIDS Res Hum Retroviruses. 2001; 17(12):1167-73. DOI: 10.1089/088922201316912772. View

Remmel R, Kawle S, Weller D, Fletcher C . Simultaneous HPLC assay for quantification of indinavir, nelfinavir, ritonavir, and saquinavir in human plasma. Clin Chem. 2000; 46(1):73-81. View

Hladik F, McElrath M . Setting the stage: host invasion by HIV. Nat Rev Immunol. 2008; 8(6):447-57. PMC: 2587276. DOI: 10.1038/nri2302. View

McMichael A, Haynes B . Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nat Immunol. 2012; 13(5):423-7. PMC: 3652652. DOI: 10.1038/ni.2264. View

Nowacek A, Balkundi S, McMillan J, Roy U, Martinez-Skinner A, Mosley R . Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. J Control Release. 2010; 150(2):204-11. PMC: 3065529. DOI: 10.1016/j.jconrel.2010.11.019. View

Mudigonda K, Jukanti R, Apte S, Ajjala D, Shrivastava W, Kandikere V . HPLC quantification of the HIV-1 protease inhibitor saquinavir in brain and testis of mice. Biomed Chromatogr. 2006; 20(10):1028-32. DOI: 10.1002/bmc.631. View

10.

Flexner C . Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits. Annu Rev Pharmacol Toxicol. 2000; 40:649-74. DOI: 10.1146/annurev.pharmtox.40.1.649. View

11.

Quinn T, Overbaugh J . HIV/AIDS in women: an expanding epidemic. Science. 2005; 308(5728):1582-3. DOI: 10.1126/science.1112489. View

12.

das Neves J, Amiji M, Bahia M, Sarmento B . Nanotechnology-based systems for the treatment and prevention of HIV/AIDS. Adv Drug Deliv Rev. 2009; 62(4-5):458-77. DOI: 10.1016/j.addr.2009.11.017. View

13.

Kim P, Read S . Nanotechnology and HIV: potential applications for treatment and prevention. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010; 2(6):693-702. DOI: 10.1002/wnan.118. View

14.

Owen D, Katz D . A vaginal fluid simulant. Contraception. 1999; 59(2):91-5. DOI: 10.1016/s0010-7824(99)00010-4. View

15.

CARPENTER C, Cooper D, Fischl M, Gatell J, Gazzard B, Hammer S . Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2000; 283(3):381-90. DOI: 10.1001/jama.283.3.381. View

16.

Jilek B, Zarr M, Sampah M, Rabi S, Bullen C, Lai J . A quantitative basis for antiretroviral therapy for HIV-1 infection. Nat Med. 2012; 18(3):446-51. PMC: 3296892. DOI: 10.1038/nm.2649. View

17.

Whaley K, Hanes J, Shattock R, Cone R, Friend D . Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines. Antiviral Res. 2010; 88 Suppl 1:S55-66. DOI: 10.1016/j.antiviral.2010.09.006. View

18.

das Neves J, Michiels J, Arien K, Vanham G, Amiji M, Bahia M . Polymeric nanoparticles affect the intracellular delivery, antiretroviral activity and cytotoxicity of the microbicide drug candidate dapivirine. Pharm Res. 2011; 29(6):1468-84. DOI: 10.1007/s11095-011-0622-3. View

19.

Panyam J, Labhasetwar V . Dynamics of endocytosis and exocytosis of poly(D,L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm Res. 2003; 20(2):212-20. DOI: 10.1023/a:1022219003551. View

20.

Kuo Y, Yu H . Expression of ornithine decarboxylase during the transport of saquinavir across the blood-brain barrier using composite polymeric nanocarriers under an electromagnetic field. Colloids Surf B Biointerfaces. 2011; 88(2):627-34. DOI: 10.1016/j.colsurfb.2011.07.053. View